Please login to the form below

Not currently logged in
Email:
Password:

J&J's Jane Griffiths named global head of Actelion

Appointment will effect once Swiss biotech's acquisition is completed

Actelion J&J Janssen Jane Griffiths

Johnson & Johnson has picked Jane Griffiths to serve as global head of Actelion, the Swiss biotech it is in the process of acquiring through a $30bn deal.

Griffiths is currently company group chairman at J&J’s Janssen EMEA company and will step into her new role once its purchase of Actelion is completed.

J&J said it anticipated closing the deal ‘towards the end of the second quarter 2017’. At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).

Prior to leading Janssen EMEA, Griffith was responsible for the EMEA market access unit, and her previous roles also include serving as international vice president for Janssen-Cilag Northern Europe.

The completion of J&J’s acquisition will also see Actelion’s chief operating officer Otto Schwarz retire, though he will work closely with Griffiths for a 12-month period after the deal goes through.

Actelion’s CEO Jean-Paul Clozel said: "I would like to thank Otto for his very significant contributions to the success of Actelion in the almost nine years since he joined the company.

“Under his leadership Tracleer was built into a global brand with almost 1.7 billion Swiss francs in peak sales. He also led and managed the highly successful launches of Opsumit, Uptravi and Veletri, thus replacing the leading drug in the category with a diversified, outcome-based portfolio, which has a strong long-term growth potential to achieve leading positions in shaping the treatment paradigms in PAH, an achievement which is a rare feat in our industry."

Clozel will also take on new responsibilities, keeping control of Actelion’s early-stage pipeline, which will be spun-off into a new biotech that he will helm.

16th May 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...